Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Transplant Cell Ther. 2024 Jul;30(7):726.e1-726.e8. doi: 10.1016/j.jtct.2024.03.015. Epub 2024 Mar 16.
Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory mantle cell lymphoma (MCL). During a fludarabine shortage, we used bendamustine as an alternative to standard cyclophosphamide/fludarabine (cy/flu) lymphodepletion (LD) prior to brexu-cel. We assessed MCL patient outcomes as well as CAR T-cell expansion and persistence after brexu-cel following bendamustine or cy/flu LD at our center. This was a retrospective single institution study that utilized prospectively banked blood and tissue samples. Clinical efficacy was assessed by 2014 Lugano guidelines. CAR T-cell expansion and persistence in peripheral blood were assessed on day 7 and at ≥month 6 for patients with available samples. Seventeen patients received bendamustine and 5 received cy/flu. For the bendamustine cohort, 14 (82%) received bridging therapy and 4 (24%) had CNS involvement. Fifteen patients (88%) developed CRS with 4 (24%) ≥grade 3 events. Six (35%) patients developed ICANS with 4 (24%) events ≥grade 3. No patient had ≥grade 3 cytopenias at day 90. Best objective (BOR) and complete response (CRR) rates were 82% and 65%, respectively. At 24.5 months median follow-up, 12-month progression-free survival (PFS) was 45%, 24-month PFS was 25%, and median duration of response was 19 months. Median OS was not reached. BOR was 25% (1/4) for patients with CNS involvement. CAR transgene expansion after bendamustine LD was observed on day 7 in all (4/4) patients tested and persisted at ≥6 months (2/2), regardless of response. Bendamustine LD before brexu-cel for MCL is feasible and safe with a lower frequency and shorter duration of cytopenias than reported for cy/flu. Both CAR T-cell expansion and persistence were observed after bendamustine LD. Outcomes appear comparable to the real world outcomes reported with cy/flu LD.
布雷昔单抗(brexu-cel)是一种自体 CD19 导向嵌合抗原受体(CAR)T 细胞疗法,获批用于治疗复发/难治性套细胞淋巴瘤(MCL)。在氟达拉滨短缺期间,我们使用苯达莫司汀替代标准的环磷酰胺/氟达拉滨(cy/flu)淋巴细胞耗竭(LD),用于 brexu-cel 治疗之前。我们评估了在我们中心接受苯达莫司汀或 cy/flu LD 后,接受 brexu-cel 治疗的 MCL 患者的结局以及 CAR T 细胞的扩增和持续存在。这是一项回顾性单中心研究,利用前瞻性储存的血液和组织样本。临床疗效评估采用 2014 年卢加诺指南。对于有可用样本的患者,在第 7 天和≥第 6 个月评估 CAR T 细胞在外周血中的扩增和持续存在。17 例患者接受苯达莫司汀治疗,5 例患者接受 cy/flu 治疗。对于苯达莫司汀组,14 例(82%)接受了桥接治疗,4 例(24%)有中枢神经系统受累。15 例(88%)患者发生 CRS,其中 4 例(24%)为≥3 级事件。6 例(35%)患者发生 ICANS,其中 4 例(24%)事件为≥3 级。无患者在第 90 天发生≥3 级血液学毒性。最佳客观缓解率(BOR)和完全缓解率(CRR)分别为 82%和 65%。在中位随访 24.5 个月时,12 个月无进展生存率(PFS)为 45%,24 个月 PFS 为 25%,中位缓解持续时间为 19 个月。中位总生存期(OS)尚未达到。有中枢神经系统受累的患者的 BOR 为 25%(1/4)。在接受苯达莫司汀 LD 治疗的所有患者(4/4)中,在第 7 天观察到 CAR 转基因扩增,并在≥6 个月时持续存在(2/2),无论反应如何。苯达莫司汀用于 MCL 的 brexu-cel 前 LD 是可行且安全的,与报告的 cy/flu LD 相比,血液学毒性的频率更低,持续时间更短。在接受苯达莫司汀 LD 治疗后,CAR T 细胞的扩增和持续存在均得到观察。结果与报告的 cy/flu LD 真实世界结果相当。